| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4023924 | Journal Français d'Ophtalmologie | 2010 | 7 Pages |
Abstract
Subconjunctival bevacizumab injections were effective and safe in reducing corneal neovascularization within the first four months. Meanwhile, improving vision may provide additional strategies.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
J. Gueudry, F. Richez, B. Tougeron-Brousseau, O. Genevois, M. Muraine,